Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brain Cancer
U.S. FDA grants orphan drug status to monoclonal antibody for brain cancer
December 28th, 2004
YM BioSciences Inc. (YMI), a cancer drug development company, and its subsidiary CIMYM Inc., announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation to their EGF receptor monoclonal antibody, TheraCIM hR3, for treating glioma (brain cancer). The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. Orphan drug designation is granted to products that treat conditions affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides eligibility for a special 7-year period of...
Source: Cancer Weekly (2004-12-28)
|
